Skip to content

Natália Piacentini

Laboratory of Experimental Neurology, Graduate Program in Health Sciences, University of Southern Santa Catarina (UNESC), Criciúma, Santa Catarina, Brazil.

2 papers in the library · 15 citations · publishing 2025

Papers

Ayahuasca Pretreatment Prevents Sepsis-Induced Anxiety-Like Behavior, Neuroinflammation, and Oxidative Stress, and Increases Brain-Derived Neurotrophic Factor.

Molecular neurobiology May 1, 2025 Rick Wilhiam de Camargo, Larissa Joaquim, Richard Simon Machado et al. 13 citations

Pretreatment with the psychoactive decoction Ayahuasca (AYA) for three days before inducing sepsis in rats reduced anxiety-like behaviors and neuroinflammation. AYA increased time spent in the open arms of an elevated plus maze and prevented excessive grooming and rearing, indicating anxiolytic effects. It raised levels of the anti-inflammatory cytokine interleukin-4 in the prefrontal cortex and cortex and brain-derived neurotrophic factor in the cortex. AYA also increased myeloperoxidase activity in the prefrontal cortex and hippocampus while decreasing nitrite/nitrate concentrations across multiple brain regions, suggesting enhanced neutrophil activation and reduced nitric oxide signaling. Additionally, AYA prevented lipid peroxidation in the prefrontal cortex, hippocampus, and cortex. These findings suggest AYA may protect against sepsis-induced neuroinflammation, oxidative stress, and anxiety-like symptoms.

Cannabidiol reverses myeloperoxidase hyperactivity in the prefrontal cortex and striatum, and reduces protein carbonyls in the hippocampus in a ketamine-induced schizophrenia rat model.

Schizophrenia research April 1, 2025 Sofia de Almeida Queiroz, Linério Ribeiro de Novais Junior, Anita Beatriz Pacheco de Carvalho et al. 2 citations

In a rat model of schizophrenia induced by ketamine, cannabidiol (CBD) restored rearing behavior (a measure of exploratory activity) without causing anhedonia-like behavior, whereas risperidone further reduced rearing and induced anhedonia-like effects in control rats. CBD reversed ketamine-induced increases in myeloperoxidase activity in the prefrontal cortex and striatum and protein carbonyls in the hippocampus, while risperidone reduced protein carbonyls in the prefrontal cortex and lowered the nitrite/nitrate ratio in the hypothalamus. Both compounds reduced oxidative stress and neuroinflammation in the striatum, hippocampus, and prefrontal cortex, but CBD did so more broadly and without the side effects seen with risperidone. These findings suggest CBD's antipsychotic effects may stem from its antioxidant and anti-inflammatory properties.